CARLOS VICENTE SERRANO JUNIOR
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina
18 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 18
conferenceObject Superiority of prothrombin complex concentrate versus frozen fresh plasma in cardiologic patients with coumarin intoxication(2016) SOEIRO, A.; CESAR, M. C.; BISELLI, B.; BOSSA, A. S.; ARAUJO, V. A.; HAJJAR, L. A.; LEAL, T. C. A. T.; SOEIRO, M. C. F. A.; VELLA, J. P.; SERRANO JR., C. V.; OLIVEIRA JR., M. T.conferenceObject Regression of atherosclerotic plaques of cholesterol-fed rabbits by combined chemotherapy of paclitaxel and methotrexate carried in lipid core nanoparticles(2017) GOMES, F. T. Torres; MARANHAO, R. C.; TAVARES, E. R.; CARVALHO, P. O.; MATTOS, F. R.; MACHADO, T.; HIGUCHI, M. L.; HATAB, S. A.; FILHO, R. Kalil; SERRANO JUNIOR, C. V.conferenceObject Defective function of hdl particles in familial apolipoprotein A-I deficiency: relevance of alterations in the lipidome(2014) RACHED, F.; SANTOS, R. Dos; MINAME, M.; LHOMME, M.; DAUTEILLE, C.; SERRANO JR., C. V.; CHAPMAN, J.; KONTUSH, A.conferenceObject Application of SYNTAX score I, II and residual SYNTAX as predictors of long-term clinical outcomes after coronary artery bypass grafting(2019) MARTINS, E. B.; HUEB, W.; LIMA, E. G.; REZENDE, P. C.; GARZILLO, C. L.; CARVALHO, G. F.; CARVALHO, F. P. C.; LINHARES FILHO, J. P. P.; BATISTA, D. V.; SILVA, R. R.; BOROS, G. A. B.; AZEVEDO, D. F. C.; SERRANO JUNIOR, C. V.; RAMIRES, J. A. F.; KALIL FILHO, R.- Long-term analysis of left ventricular ejection fraction in patients with stable multivessel coronary disease undergoing medicine, angioplasty or surgery: 10-year follow-up of the MASS II trial(2013) GARZILLO, Cibele Larrosa; HUEB, Whady; GERSH, Bernard J.; LIMA, Eduardo Gomes; REZENDE, Paulo Cury; HUEB, Alexandre Ciappina; VIEIRA, Ricardo D'Oliveira; FAVARATO, Desiderio; PEREIRA, Alexandre Costa; SOARES, Paulo Rogerio; SERRANO JR., Carlos Vicente; RAMIRES, Jose Antonio Franchini; KALIL FILHO, RobertoBackground Assuming that coronary interventions, both coronary bypass surgery (CABG) and percutaneous coronary intervention (PCI), are directed to preserve left ventricular function, it is not known whether medical therapy alone (MT) can achieve this protection. Thus, we evaluated the evolution of LV ejection fraction (LVEF) in patients with stable coronary artery disease (CAD) treated by CABG, PCI, or MT as a post hoc analysis of a randomized controlled trial with a follow-up of 10 years. Methods Left ventricle ejection fraction was assessed with transthoracic echocardiography in patients with multivessel CAD, participants of the MASS II trial before randomization to CABG, PCI, or MT, and re-evaluated after 10 years of follow-up. Results Of the 611 patients, 422 were alive after 10.32 1.43 years. Three hundred and fifty had LVEF reassessed: 108 patients from MT, 111 from CABG, and 131 from PCI. There was no difference in LVEF at the beginning (0.61 0.07, 0.61 0.08, 0.61 0.09, respectively, for PCI, CABG, and MT, P 0.675) or at the end of follow-up (0.56 0.11, 0.55 0.11, 0.55 0.12, P 0.675), or in the decline of LVEF (reduction delta of 7.2 17.13, 9.08 18.77, and 7.54 22.74). Acute myocardial infarction (AMI) during the follow-up was associated with greater reduction in LVEF. The presence of previous AMI (OR: 2.50, 95 CI: 1.404.45; P 0.0007) and during the follow-up (OR: 2.73, 95 CI: 1.255.92; P 0.005) was associated with development of LVEF 45. Conclusion Regardless of the therapeutic option applied, LVEF remains preserved in the absence of a major adverse cardiac event after 10 years of follow-up.
conferenceObject Effect of myocardial ischemia in diabetic and non-diabetic patients: long-term follow-up of MASS registry(2020) CARVALHO, F. Camara De; HUEB, W.; LIMA, E. G.; LINHARES FILHO, J. P. P.; RIBEIRO, M. O. L.; MARTINS, E. B.; V, D. Batista; GARZILLO, C. L.; RIBAS, F. F.; BOROS, G. A. B.; REZENDE, P. C.; V, C. Serrano Junior; RAMIRES, J. A. F.; KALIL FILHO, R.conferenceObject Beneficial effects of red wine intake upon gut microbiota and parallel effects upon plasma metabolomics(2019) HAAS, E.; FAVARATO, D.; LAURINDO, F. R. M.; SAAD, M. J. A.; SANTOS, A.; SERRANO JR., C. V.; CESAR, L. A. M.; ISOSAKI, M.; LIBBY, P.; LUZ, P. L. DaconferenceObject T1 mapping for myocardial tissue evaluation in patients with ischemia and stable coronary artery disease: MASS V-Trial Study Group(2020) RIBEIRO, M.; HUEB, W.; REZENDE, P. C.; ROCHITTE, C. E.; NOMURA, C. H.; MORAIS, T.; LIMA, E. G.; BOROS, G. A. B.; RIBAS, F. F.; CARVALHO, F. P. C.; CARVALHO, G. F.; MOCHA, M. R.; V, C. Serrano; RAMIRES, J. A. F.; KALIL FILHO, R.conferenceObject Myocardial injury assessed by T1 mapping after on-pump and off-pump coronary artery bypass grafting. a pre-specified analysis of mass V trial(2019) DALLAZEN, A. R.; HUEB, W.; REZENDE, P. C.; BOROS, G. A. B.; RIBAS, F. F.; NOMURA, C. H.; ROCHITTE, C. E.; MORAIS, T.; LIMA, E. G.; MARTINS, E. B.; CARVALHO, G. F.; RIBEIRO, M. O. L.; SERRANO JUNIOR, C. V.; RAMIRES, J. A. F.; KALIL FILHO, R.conferenceObject Evaluation of periprocedural inflammatory response and myocardial injury associated with cigarette smoking in patients undergoing elective percutaneous coronary intervention(2016) GARZILLO, C. L.; BRITO JR., F. S.; MATTOS, F. R.; GAZ, M.; RACHED, F. H.; NASCIMENTO, T. C. D. C.; PERIN, M. A.; KALIL-FILHO, R.; SERRANO JR., C. V.